Coeptis Therapeutics (COEP, Financial) has announced a definitive agreement to merge with Z Squared, a move that will transform Z Squared into a wholly-owned subsidiary of Coeptis. This strategic business combination will see Z Squared shareholders exchanging their equity for 9,000 U.S. based Dogecoin (DOGE) mining machines upon completion of the merger.
The Boards of both companies have given their approval, although the merger still requires standard regulatory approvals, continued Nasdaq listing, and shareholder consent from both entities. Coeptis plans to divest its biopharmaceutical operations while retaining them separately post-merger, allowing the new entity to focus on digital asset mining operations. The merger is projected to close by the third quarter of 2025, contingent upon meeting all necessary conditions.
Following the merger, Coeptis is expected to rebrand and operate under the Z Squared name, maintaining its listing on the Nasdaq Capital Market. The newly combined entity will center its efforts on expanding Z Squared's expertise in digital asset mining, especially focusing on Dogecoin. Dogecoin is a prominent digital currency with a market capitalization exceeding $20 billion, and its blockchain utilizes a proof-of-work mechanism to reward mining operations.
Leadership of the merged company will transition to Z Squared executives, with David Halabu assuming the role of CEO and Michelle Burke as COO. Dave Mehalick, the current President and CEO of Coeptis, will step down from the Board of Directors once the merger is finalized.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Coeptis Therapeutics Holdings Inc (COEP, Financial) is $3.00 with a high estimate of $3.00 and a low estimate of $3.00. The average target implies an downside of 75.94% from the current price of $12.47. More detailed estimate data can be found on the Coeptis Therapeutics Holdings Inc (COEP) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Coeptis Therapeutics Holdings Inc's (COEP, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
